Survival analysis indicated that ccRCC patients with high MAP2K2 expression level showed shorter OS and disease-free survival (DFS) compared to those with low MAP2K2 expression level (Figure 2B). The gene discussed is MAP2K2; the disease is nonpapillary renal cell carcinoma.